Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir

Autor:	Hayato Baba, Kazuto Tajiri, Kohei Nagata, Kengo Kawai, Masami Minemura, Toshiro Sugiyama
Jazyk:	angličtina
Rok vydání:	2016
Předmět:	Cirrhosis Direct-acting agent Hepatitis C virus P-glycoprotein Hyperbilirubinemia Diseases of the digestive system. Gastroenterology RC799-869
Zdroj:	Case Reports in Gastroenterology, Vol 10, Iss 2, Pp 352-359 (2016)
Druh dokumentu:	article
ISSN:	1662-0631
DOI:	10.1159/000447486
Popis:	Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis. We encountered a patient exhibiting severe hyperbilirubinemia during combined therapy, which is an unreported side effect of DCV and ASV. A 78-year-old woman with cirrhosis developed hyperbilirubinemia >10 mg/dl without transaminitis 3 weeks after starting combined therapy. We suspected DAAs-induced liver disorder and discontinued treatment, which resulted in the improvement of hyperbilirubinemia. Caution is required in the use of DAAs for patients with advanced cirrhosis.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/e2072568831a4f62a0185f32620a5207 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.